Mesothelioma Chemoperfusion Trial Shows Impressive Results

Study statistics show the benefits of the novel transarterial chemoperfusion treatment being used successfully at the Moffitt Cancer Center in Tampa for patients with relapsed pleural mesothelioma. Russell Lamkins — working on the roof of a neighbor’s house — shows them even better. He is living proof. This latest mesothelioma treatment has potential. Lamkins, 73, was first diagnosed with mesothelioma in 2014. He was the second patient to enroll in the mesothelioma clinical trial in March 2016, soon after standard-of-care chemotherapy and immunotherapy had failed him. “At that point, I had no choice,” he said. Principal investigator Dr. Bela Kis presented impressive results from his groundbreaking clinical trial at the virtual Society of Interventional Radiology 2020 Scientific Meeting June 14, about the same time Lamkins was cutting his grass and trimming the hedges. “It [the treatment] seems to be working for me,” Lamkins said from his home in southwest Florida. “If not, I would have been gone a long time ago. I’d be dead by now.” Chemoperfusion Procedure Is Minimally Invasive Lamkins has emerged today as an inspiration, a beacon of hope for many with this aggressive, incurable disease, and a shining example of how important a mesothelioma clinical trial can be. “We can’t do magic, but we’ve shown we can extend survival and improve patients’ lives with this treatment,” Kis told The Mesothelioma Center and Asbestos.com. “I believe in the fut...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news